Does folate supplementation prevent neural tube defects?
Strong EvidenceYES
Folate supplementation before and during early pregnancy definitively prevents the majority of neural tube defects. This is supported by landmark RCTs and has led to mandatory food fortification policies in over 80 countries.
The Verdict
Folate supplementation before and during early pregnancy definitively prevents the majority of neural tube defects. This is supported by landmark RCTs and has led to mandatory food fortification policies in over 80 countries.
What the Evidence Shows
The relationship between folate (vitamin B9) and neural tube defects (NTDs) is one of the most important public health discoveries of the 20th century. The MRC Vitamin Study (1991) was the landmark multicenter RCT that provided definitive proof: periconceptional folic acid supplementation (4mg/day) reduced NTD recurrence by 72% in women with a prior affected pregnancy. This was rapidly confirmed by Czeizel and Dudas (1992) who demonstrated that a multivitamin containing 0.8mg folic acid prevented first-occurrence NTDs entirely in their trial population. The biological mechanism involves folate's essential role in one-carbon metabolism and DNA synthesis during the critical period of neural tube closure (days 21-28 post-conception, often before pregnancy is recognized). This timing explains why supplementation must begin before conception to be effective. Subsequent Cochrane reviews have confirmed the benefit with high certainty. The evidence was so compelling that over 80 countries now mandate folic acid fortification of flour or grain products, resulting in 20-50% reductions in NTD prevalence where implemented. The recommended dose for prevention of first occurrence is 400-800 mcg/day starting at least one month before conception. While concerns about potential cancer promotion from high-dose folic acid have been raised in meta-analyses, these relate to sustained high supplementation in older adults, not periconceptional use.
Evidence Quality
2
Meta-Analyses
4
RCTs
10
Observational
Important Caveats
- ⚠️ Supplementation must begin before conception (neural tube closes by day 28)
- ⚠️ Does not prevent all NTDs — approximately 30% are folate-resistant
- ⚠️ High-dose folic acid supplementation in non-pregnant adults may have different risk profiles
- ⚠️ Genetic variants in MTHFR enzyme may affect folate metabolism
- ⚠️ Food fortification has reduced but not eliminated NTDs in fortified countries
Population Studied
Women of reproductive age planning pregnancy; populations with and without prior NTD-affected pregnancies
Dosage
400 mcg/day for primary prevention; 4 mg/day for women with prior NTD-affected pregnancy; begin at least 1 month before conception
Duration
Must begin before conception and continue through first 12 weeks of pregnancy; neural tube closes by day 28 post-conception
Supporting Studies (3)
Prevention of neural tube defects: results of the Medical Research Council Vitamin Study
RCTMRC Vitamin Study Research Group. · The Lancet (1991)
Periconceptional folic acid supplementation (4mg/day) reduced neural tube defect recurrence by 72% in a multicenter RCT of 1,817 women with a prior affected pregnancy.
View paper (DOI) →Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation
RCTCzeizel AE, Dudas I. · New England Journal of Medicine (1992)
Periconceptional multivitamin containing 0.8mg folic acid completely prevented first-occurrence neural tube defects in a Hungarian RCT of 4,753 women.
View paper (DOI) →Periconceptional folic acid supplementation to prevent neural tube defects
Meta-AnalysisDe-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, Rayco-Solon P. · Cochrane Database of Systematic Reviews (2015)
Cochrane review of 5 RCTs confirmed folic acid supplementation reduces neural tube defects by approximately 69%, with consistent results across study populations.
View paper (DOI) →Contradicting Studies (1)
Folic acid supplementation and cancer risk: a meta-analysis of randomised controlled trials
Meta-AnalysisVollset SE, Clarke R, Lewington S, et al. · The Lancet (2013)
Meta-analysis of 13 RCTs found that folic acid supplementation did not significantly reduce or increase overall cancer incidence, but raised concerns about potential cancer promotion with long-term high-dose use in older adults.
Why this disagrees:
While not directly contradicting NTD prevention, this raises concerns about broad folic acid fortification potentially affecting cancer risk in non-target populations, adding nuance to universal supplementation policies.